These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22202242)

  • 21. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer.
    de Jong RA; Nijman HW; Boezen HM; Volmer M; Ten Hoor KA; Krijnen J; van der Zee AG; Hollema H; Kema IP
    Int J Gynecol Cancer; 2011 Oct; 21(7):1320-7. PubMed ID: 21720257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical Evaluation of Indoleamine 2, 3-Dioxygenase in the Serum of Patients with Locally Advanced Breast Cancer during Mohs Paste Treatment].
    Kubota H; Sakurai K; Fujisaki S; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T; Saga R; Makishima M
    Gan To Kagaku Ryoho; 2017 Oct; 44(10):915-917. PubMed ID: 29066694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.
    Zhao Y; Wei L; Liu J; Li F
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):77-93. PubMed ID: 31844921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity.
    Hoshi M; Ito H; Fujigaki H; Takemura M; Takahashi T; Tomita E; Ohyama M; Tanaka R; Saito K; Seishima M
    Leuk Res; 2009 Jan; 33(1):39-45. PubMed ID: 18639341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
    Watanabe N; Ootawa Y; Kodama K; Kaide A; Ootsuka N; Matsuoka J
    Breast Cancer; 2010 Oct; 17(4):247-53. PubMed ID: 19728030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy.
    Onesti CE; Boemer F; Josse C; Leduc S; Bours V; Jerusalem G
    J Transl Med; 2019 Jul; 17(1):239. PubMed ID: 31337401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer.
    Salvadori ML; da Cunha Bianchi PK; Gebrim LH; Silva RS; Kfoury JR
    Med Oncol; 2015 Nov; 32(11):248. PubMed ID: 26442514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
    Zielinski C; Beslija S; Mrsic-Krmpotic Z; Welnicka-Jaskiewicz M; Wiltschke C; Kahan Z; Grgic M; Tzekova V; Inbar M; Cervek J; Chernozemsky I; Szanto J; Spanik S; Wagnerova M; Ghilezan N; Pawlega J; Vrbanec D; Khamtsov D; Soldatenkova V; Brodowicz T
    J Clin Oncol; 2005 Mar; 23(7):1401-8. PubMed ID: 15735116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral kynurenine/tryptophan ratio is not a reliable marker of systemic indoleamine 2,3-dioxygenase: A lesson drawn from patients on hemodialysis.
    Chen Y; Xie Z; Xiao C; Zhang M; Li Z; Xie J; Zhang Y; Zhao X; Zeng P; Mo L; Liang X; Shi W
    Oncotarget; 2017 Apr; 8(15):25261-25269. PubMed ID: 28445957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Breast cancer: HER2 changes one's cards on the table].
    Lopez M
    Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis].
    Sakurai K; Fujisaki S; Nagashima S; Maeda T; Shibata M; Gonda K; Tomita R; Suzuki S; Hara Y; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1776-8. PubMed ID: 23267883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia.
    Suzuki Y; Suda T; Yokomura K; Suzuki M; Fujie M; Furuhashi K; Hahimoto D; Enomto N; Fujisawa T; Nakamura Y; Inui N; Nakano Y; Nakamura H; Chida K
    J Infect; 2011 Sep; 63(3):215-22. PubMed ID: 21784100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
    Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
    Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
    J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation.
    Brandacher G; Cakar F; Winkler C; Schneeberger S; Obrist P; Bösmüller C; Werner-Felmayer G; Werner ER; Bonatti H; Margreiter R; Fuchs D
    Kidney Int; 2007 Jan; 71(1):60-7. PubMed ID: 17136028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
    Wang B; Fu JF; Hong ZW
    Ai Zheng; 2009 Mar; 28(3):292-6. PubMed ID: 19619445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Safety and efficacy of weekly paclitaxel followed by FEC100 as primary systemic therapy for breast cancer].
    Naito K; Oura S; Yoshimasu T; Tamaki T; Ohta F; Nakamura R; Shimizu Y; Kiyoi M; Hirai Y; Miyasaka M; Okamura Y
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):251-4. PubMed ID: 19223740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
    Wichers MC; Koek GH; Robaeys G; Verkerk R; Scharpé S; Maes M
    Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
    Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
    Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.